May 14, 2025

AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas

January 10, 2025

ADARx Pharmaceuticals to Present at the J.P. Morgan 43rd Annual Healthcare Conference

July 30, 2024

ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer

February 21, 2024

ADARx Pharmaceuticals to Participate in the 44th Annual Cowen Healthcare Conference

January 03, 2024

ADARx Pharmaceuticals to Present at the J.P. Morgan 42nd Annual Healthcare Conference

August 09, 2023

ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing

January 20, 2023

ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324

January 20, 2023

ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic

January 09, 2023

ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer

June 07, 2022

ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology

January 25, 2022

ADARx Pharmaceuticals Expands Leadership Team

September 08, 2021

ADARx Raises $75 Million to Advance Growing Pipeline